Search

Displaying results 331 - 340 of 9347 in total
  1. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718] … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell

  2. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    and trafficking of mature protein to the cell surface. … chaperone, aiding the conformational stability of the mutated CFTR protein.

  3. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]

  4. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa].

  5. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development … [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention

  6. Drug

    Butobarbital

    go.drugbank.com/drugs/DB01353
    ApprovedIllicit

    Butobarbital is a sedative and a hypnotic drug.

  7. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. … In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Teriparatide

    go.drugbank.com/drugs/DB06285
    ApprovedInvestigational

    [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic … [A251395] It is made up of the first amino(N)-terminal 34 amino acids of the human PTH.

  9. Drug

    Alfentanil

    go.drugbank.com/drugs/DB00802
    ApprovedIllicitInvestigational

    A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analges...

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … a myeloid malignancy in the dendritic cell lineage.